Pharmaceutical company Elan and its US partner Biogen have received backing from a Scottish health watchdog for its MS drug.
The Scottish Medicines Consortium (SMC) today advised the use of Elan's and partner Biogen's drug Tysabri in people with active relapsing remitting multiple sclerosis.
All NHS Health Boards in Scotland are now obliged to consider the SMC's advice and ensure that TYSABRI is made available to meet patient's needs.
Similar positive guidance on the drug was issued in England by the National Institute for Health and Clinical Excellence (NICE) last month.
